Generated by AI
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.
Website1851 Harbor Bay Parkway
Alameda, CA, 94502
United States
The latest articles about EXEL.
Exelixis’ leading pipeline candidate is inching closer to approval.
These catalysts could impact growth down the road.
Summary of Oct 30's posts. Generated by AI.
Summary of Jun 23's posts. Generated by AI.
Summary of Jan 13's posts. Generated by AI.
Summary of Sep 9's posts. Generated by AI.
Investors talking about EXEL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.